Treatment for advanced cervical cancer using chemoradiotherapy and additional chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of concurrent chemoradiotherapy combined with adjuvant chemotherapy in patients with locally advanced cervical cancer. It compares the outcomes of patients receiving both treatments against those receiving only chemoradiotherapy. The study utilizes advanced radiation techniques, including intensity-modulated radiation therapy and three-dimensional afterloading therapy, to enhance treatment efficacy. The aim is to clarify the role of adjuvant chemotherapy in improving disease-free and overall survival rates based on the updated 2018 FIGO staging system.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma
* FIGO stage IB3, IIA2, IIB-IVA patients in 2018
* Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment
* Aged 18-75 years
* PS score 0-1
* Serum hemoglobin \>=100\*10\^9/L, blood platelet \>= 100000/μL, absolute count of neutrophils\>=1500/μL; 7.Serum creatinine \<=1.5 UNL or creatinine clearance \>= 60 ml/min; 8.Serum bilirubin \<=1.5 UNL, AST (SGOT) and ALT (SGPT)\<= 1.5 UNL
* Sign a formal informed consent to show that they understand that the study is in line with hospital and national policies .Estimated total survival \> 6 months.

Exclusion Criteria:

* Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment
* Patients who have received neoadjuvant chemotherapy and surgery
* Patients with cognitive impairment
* Patients with any distant metastases
* Patients with any other malignancy within 5 years
* Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use contraception
* Severe bone marrow dysfunction
* Patients with bleeding tendency
* Drug abusers or alcohol addicts
* Those who are known to have a third or fourth degree allergic reaction to any treatment in the study

Where it's running

• the Fourth Affiliated Hospital of Guangxi Medical University
  Liuzhou, Guangxi, China Recruiting

Study contacts

• Principal investigator: Feng chengjun — The The Fourth Affiliated Hospital of Guangxi Medical University
• Study coordinator: Huang haixin
• Email: 13507726193@163.com
• Phone: 13507726193

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enlonstobart with chemotherapy and radiotherapy for locally advanced cervical cancer

  This study tests whether adding Enlonstobart to standard chemotherapy and chemoradiotherapy helps patients with locally advanced cervical cancer by increasing response rates and monitoring safety.

  Recruiting at 2 sites Phase 4 Tianjin Medical University Cancer Institute and Hospital · Tianjin and 1 other locations · NCT07776821

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Immunotherapy Plus Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer

  This trial tests whether adding immunotherapy and chemotherapy to carbon ion radiotherapy can help women with locally advanced cervical cancer live longer without the cancer growing.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07702838

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• Plasma ctDNA methylation-guided adjuvant chemotherapy for stage I / low-risk stage II colorectal cancer

  This trial will test whether using a blood test for ctDNA methylation one month after surgery to guide adjuvant chemotherapy (such as capecitabine) helps clear ctDNA and lower recurrence risk in adults with stage I or low-risk stage II colorectal cancer who are ctDNA-positive.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562659

• Comparing oxaliplatin plus S-1 versus docetaxel plus S-1 after surgery for stage III stomach cancer

  This trial tests whether oxaliplatin plus S-1 or docetaxel plus S-1 is better at preventing cancer recurrence in people with stage III gastric cancer after D2 gastrectomy.

  Recruiting Phase 3 Ruijin Hospital · Shaoguan, Guandong and 4 other locations · NCT07366528

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.